Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Sep 01, 2008 (Vol. 28, No. 15)

Angiogenesis and Cancer Control

URL:www.moffitt.org/moffittapps/ccj//v6n5/article2.htm
  • Organization
  • A little light
Cells in developing tumors, the story goes, require more oxygen than normal cells due to their higher metabolic rate. Indeed, it is thought that the growth of blood vessels toward tumor cells is an important step in their development. It is no surprise, therefore, that drugs suppressing angiogenesis are readily sought for the treatment of cancers. The H. Lee Moffitt Cancer Center and Research Institute hosts this rather spotty collection of information on the subject of angiogenesis and cancer control. To find the goods, you’ll need to look around. The Search Clinical Trials database is the main offering here with options for selecting on the basis of disease type, drug, therapy, and phase of the disease. Most of the other links at the site are more aimed at general info or about the institute itself.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »